Mounjaro vs Glucophage
A side-by-side look at two diabetes medications advertised on TV. Informational only — not medical advice.
| CA Mounjaro | CA Glucophage | |
|---|---|---|
| Generic name | tirzepatide | metformin |
| Drug class | GIP/GLP-1 Receptor Agonist | Biguanide |
| Treats | Type 2 diabetes | Type 2 diabetes |
| Category | Diabetes | Diabetes |
| Manufacturer | Eli Lilly | Merck/EMD (generic) |
| Year approved | 2022 | 1972 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $40M | $2M |
| Common side effects | Nausea, Diarrhea, Decreased appetite, Vomiting | Nausea, Diarrhea, Abdominal discomfort, Vitamin B12 deficiency |
Glucophage
Frequently asked questions
Is Mounjaro or Glucophage better?
Neither is universally "better." Mounjaro (tirzepatide) and Glucophage (metformin) are both used for diabetes, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Mounjaro and Glucophage?
Mounjaro is a GIP/GLP-1 Receptor Agonist made by Eli Lilly, while Glucophage is a Biguanide made by Merck/EMD (generic). See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Mounjaro has the larger estimated TV advertising budget of the two.